The Effect of Estradiol and a Combined Estradiol/Progestagen Preparation on Insulin Sensitivity in Healthy Postmenopausal Women
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Abnormalities of carbohydrate metabolism and insulin sensitivity have been reported in estrogen deficiency. Estrogen replacement appears to result in an improvement in these parameters, although progestagens may antagonize these effects. We have examined the effects of transdermal estradiol and oral norethisterone on insulin sensitivity using the hyperinsulinemic euglycemic clamp method by performing a randomized, double blind, placebo-controlled study in 22 healthy women after a surgically induced menopause. After baseline measurements, subjects were randomized to receive either transdermal 17beta-estradiol (50 microg) or matching placebo patches for 6 weeks. The subjects were then further randomized to receive either estradiol in combination with oral norethisterone (1 mg) or a matching oral placebo preparation, crossing over after 6 weeks, with assessment of insulin sensitivity at the end of each treatment. No significant increase in insulin sensitivity was observed after 6 weeks of transdermal 17beta-estradiol treatment (95% confidence interval, -0.54, 1.86; P = 0.27). Addition of norethisterone for a further 6 weeks had no detectable effect on insulin sensitivity (95% confidence interval, -1.65, 1.10; P = 0.65). The results of this study using transdermal estradiol do not support previous reports that unopposed estrogens exert potentially beneficial effects on insulin sensitivity and suggest that the addition of an oral progestagen confers no clinically important risk or benefit. It is therefore unlikely that effects on insulin sensitivity contribute appreciably to the cardioprotective benefits attributed to hormone replacement therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Isles, C. G., Hole, D. J., Hawthorne, V. M., & Lever, A. F. (1992) · The Lancet · doi:10.1016/0140-6736(92)90599-x · Cited by 277 · cited 1×
“It is less well appreciated that this is also the case in women (1), although a temporal association between loss of ovarian function at the time of the menopause and increased risk of cardiovascular disease in women has now been established (2, 3).”
Background
Cited by
for the Women’s Health Initiative Investigators, Margolis, K. L., Bonds, D. E., Rodabough, R. J., Tinker, L., Phillips, L. S., Allen, C., Bassford, T., Burke, G., Torrens, J., et al. (2004) · Diabetologia · doi:10.1007/s00125-004-1448-x · Cited by 599
“This finding, however, has not been consistent [6, 11, 15, 16, 17, 20, 38, 42, 44].”
BackgroundResultInfluentialGodsland, I. F. (2001) · Fertility and Sterility · doi:10.1016/s0015-0282(01)01699-5 · Cited by 370
Mauvais-Jarvis, F., Manson, J. E., Stevenson, J. C., & Fonseca, V. A. (2017) · Endocrine Reviews · doi:10.1210/er.2016-1146 · Cited by 341
“Duncan (113) RCT 22 35–50 6 wk t-E2 50 mg Euglycemic, hyperinsulinemic clamp GDR ←→”
BackgroundAntidiabetic actions of estrogen: Insight from human and genetic mouse models
Louet, J.-F., LeMay, C., & Mauvais-Jarvis, F. (2004) · Current Atherosclerosis Reports · doi:10.1007/s11883-004-0030-9 · Cited by 284
Gao, H., Bryzgalova, G., Hedman, E., Khan, A., Efendic, S., Gustafsson, J.-A., & Dahlman-Wright, K. (2006) · Molecular Endocrinology · doi:10.1210/me.2006-0012 · Cited by 179
Metadata
- Authors
- Duncan, A. C.
- Venue
- Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 1999-07-01
- Volume
- 84
- Issue
- 7
- Pages
- 2402-2407
- ISSN
- 0021-972X (ISSN-L)
- OpenAlex
- W2139211968
- Cited by
- 83
- References
- 1
- FWCI
- 5.32
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.